News Major shareholder announcement – BlackRock, Inc. Staff September 11, 2023 Iframe sync Post navigation Previous: Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Next: Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston More Stories Clinical Trial Healthcare News Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Staff January 13, 2026 Healthcare News Pharmaceutical CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026 Staff January 12, 2026 Healthcare News TempraMed Closes C$2.5 Million Fully Subscribed Private Placement Staff January 12, 2026
